The central goal of my research program is to elucidate the mechanism whereby the HIV genome gains entry into the cell. Our overall approach is to kinetically resolve steps in the pathway of HIV Envelope Glycoprotein (Env)-mediated membrane fusion and to uncover physical parameters underlying those steps using a variety of biochemical, biophysical, virological, and molecular and cell biological techniques. Resolution of the characteristics of these intermediates will yield insights into the mode of action of the viral envelope glycoproteins and enable us to identify potential antibodies and inhibitors that block HIV entry and prevent infection. We have studied the mode of action of small molecule antagonists of the viral coreceptors CCR5 and CXCR4 and the fusion inhibitor T20 that is in advanced clinical trials. By examining fusion kinetics of various HIV strains we found that the sensitivity of HIV to entry inhibitors correlates with envelope:coreceptor affinity, receptor density and fusion kinetics. An important implication of these findings is that individuals who express lower levels of coreceptor may respond more efficiently to entry inhibitors such as T20, whose effectiveness is dependent in part on fusion kinetics. We found that membrane microdomains enriched in cholesterol and glycosphingolipids are involved in HIV-1 entry into cells in as much as there is a necessity to recruit the fusion complexes in a limited area of the membrane to provide the high surface density of coreceptors. We are pursuing approaches to interfere with HIV-1 entry using agents that change membrane organization. These findings may show a way to interfere with HIV infection by changing cellular levels of ceramides. We have developed new methodologies that include photosensitized labeling, membrane protein purification, tandem proteolysis and Mass Spectroscopy analysis to identify domains of HIV/SIV Env that are involved in the operation of the fusion machine. Information about these domains is not accessible by current high-resolution structural determination techniques. Based on the tools acquired in these studies, we are developing photosensitized labeling as a general methodology to study nearest neighbor interactions between membrane components of signal transduction pathways in normal and transformed cells.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC008303-32
Application #
7048208
Study Section
(LECB)
Project Start
Project End
Budget Start
Budget End
Support Year
32
Fiscal Year
2004
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Jacobs, Amy; Garg, Himanshu; Viard, Mathias et al. (2008) HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development. Vaccine 26:3026-35
Dimitrov, Antony S; Jacobs, Amy; Finnegan, Catherine M et al. (2007) Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry 46:1398-401
Jacobs, Amy; Quraishi, Omar; Huang, Xicai et al. (2007) A covalent inhibitor targeting an intermediate conformation of the fusogenic subunit of the HIV-1 envelope complex. J Biol Chem 282:32406-13
Garg, Himanshu; Joshi, Anjali; Freed, Eric O et al. (2007) Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. J Biol Chem 282:16899-906
Blumenthal, Robert; Dimitrov, Dimiter S (2007) Targeting the sticky fingers of HIV-1. Cell 129:243-5
Fox, T E; Finnegan, C M; Blumenthal, R et al. (2006) The clinical potential of sphingolipid-based therapeutics. Cell Mol Life Sci 63:1017-23
Rawat, Satinder Singh; Viard, Mathias; Gallo, Stephen A et al. (2006) Sphingolipids, cholesterol, and HIV-1: a paradigm in viral fusion. Glycoconj J 23:189-97
Finnegan, Catherine M; Blumenthal, Robert (2006) Fenretinide inhibits HIV infection by promoting viral endocytosis. Antiviral Res 69:116-23
Wexler-Cohen, Yael; Johnson, Benitra T; Puri, Anu et al. (2006) Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J Biol Chem 281:9005-10
Gallo, Stephen A; Wang, Wei; Rawat, Satinder S et al. (2006) Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 281:18787-92

Showing the most recent 10 out of 42 publications